Potent inhibition of CYP2D6 by haloperidol metabolites: Stereoselective inhibition by reduced haloperidol

British Journal of Clinical Pharmacology

Volumn 51, Issue 1, 2001, Pages 45-52

  Shin, Jae Gook ^a   Kane, Khadidjatou ^a   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CYP2D6; Enantiomer; Haloperidol; Inhibition; Interaction; Metabolites; Reduced haloperidol

Indexed keywords

3 (4 FLUOROBENZOYL)PROPIONIC ACID; 4 (4 CHLOROPHENYL) 1 [4 (4 FLUOROPHENYL) 4 HYDROXYBUTYL] 1,2,3,6 TETRAHYDROPYRIDINE; 4 (4 CHLOROPHENYL) 1 [4 (4 FLUOROPHENYL) 4 OXYBUTYL]PYRIDINIUM DERIVATIVE; 4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; HALOPERIDOL; LEVALLORPHAN; O DEMETHYLASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG EFFECT; DRUG METABOLISM; DRUG OXIDATION; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL; STEREOCHEMISTRY;

BINDING, COMPETITIVE; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP2D6; DEXTRORPHAN; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; HUMANS; KINETICS; MICROSOMES, LIVER; PHENOLS; PROPANOLS; STEREOISOMERISM;

EID: 0035142516     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.01313.x     Document Type: Article

References (47)

1. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients - A prescription database study
2. Increase of plasma a concentration of m-chlorophenylpiperazine, but not trazodon, with low-dose haloperidol
3. Thioridazine interferences with imipramine metabolism and measurement
4. Drug interactions with antipsychotic agents
5. Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem
6. Oxidation of reduced haloperidol to haloperidol: Involvement of human CYPIID6 (spartein/debrisoquine monooxygenase)
7. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients
8. Pharmacokinetics and drug interactions: Update for new antipsychotics
9. Phenothiazines with aliphatic side chain
10. Metabolism of haloperidol: Clinical implications and unanswered questions
11. Haloperidol metabolism in psychiatric patients: Importance of glucuronidation and carbonyl reduction
12. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol
13. Characterization of the cytochrome P450 isozymes in the in vitro N-dealkylation of haloperidol
14. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation
15. In vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol
16. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome P450IID6
17. Metabolites of halopefidol display preferential activity at sigma receptors compared to dopamine D-2 receptors
18. Prolactin releasing potencies of antipsychotic and related nonpsychotic compounds in female rats: Relation to clinical potencies
19. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs
20. Preliminary behavioral and pharmacological studies on the haloperidol metabolite reduced haloperidol
21. Effect of a pyridinium metabolites derived from haloperidol on the acitivities of striatal tyrosine hydroxylase in freely moving rats
22. +) towards cultured dopaminergic neuroblastoma cells
23. +-like toxicity of pyridinium metabolites derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies
24. Synthesis of the enantiomers of reduced haloperidol
25. Stereoselective reduction of haloperidol in human tissues
26. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and unknown P450 enzyme
27. Application of Bradford's protein assay to adrenal gland subcellular fractions
28. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver
29. Evaluation of omeprazole and lansoprazole as inhibitor of cytochrome P450 isoforms
30. + found in rat brain following IP administration of HP
31. Inhibition of CYP2D6 by antipsychotic drugs
32. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems
33. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes
34. Metabolism of haloperidol
35. Plasma haloperidol and clinical response: A role for reduced haloperidol in antipsychotic acitivity
36. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol
37. Haloperidol and reduced haloperidol plasma level in Chinese vs. non-Chinese psychiatric patients
38. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol
39. Quantitative analysis of one pyridinium metabolite of haloperidol and identification of another in schizophrenic patients
40. Simultaneous determination of haloperidol and its neurotoxic metabolite in plasma and brain tissue from schizophrenic patients treated with haloperidol using HPLC and solid-phase extraction
41. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients
42. Formation of pyridinium species of haloperidol in human liver and brain
43. Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: Is HPTP an intermediate?
44. Development of a pharmacophore for inhibition of human liver cytochrome P4502D6: Molecular modeling and inhibition studies
45. Haloperidol reductase in human and guinea pig livers
46. Reduced haloperidol/haloperidol ratios in plasma: Polymorphism in Japanese psychiatric patients